Bluttests und Fragebögen zur Untersuchung der Einhaltung präventiver Schluckübungen bei Teilnehmern mit metastasiertem Kopf- und Halskrebs
Modellierung der Einhaltung präventiver Schluckübungen bei Kopf- und Halskrebs
This trial uses blood tests and questionnaires to study how well participants with head and neck cancer that has spread to other places in the body adhere to swallowing exercises to prevent future disease. Using blood tests to study cytokines (proteins related to the immune system) may help doctors learn if certain levels of cytokines affect whether or not side effects occur and if they put participants at risk for future disease. Questionnaires may help doctors learn about the reasons head and neck cancer participants may or may not follow the swallowing exercises that they are asked to perform after receiving radiation treatments.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
- HPV-vermitteltes (p16-positiv) Oropharynxkarzinom im klinischen Stadium III AJCC v8
- Stadium III Hypopharynxkarzinom AJCC v8
- Kehlkopfkrebs im Stadium III AJCC v8
- Stadium III Oropharynxkarzinom (p16-negativ) AJCC v8
- Stadium IV Hypopharynxkarzinom AJCC v8
- Kehlkopfkrebs Stadium IV AJCC v8
- Stadium IV Oropharynxkarzinom (p16-negativ) AJCC v8
- HPV-vermitteltes (p16-positiv) Oropharynxkarzinom im klinischen Stadium I AJCC v8
- HPV-vermitteltes (p16-positiv) Oropharynxkarzinom im klinischen Stadium II AJCC v8
- Pathologisches Stadium I HPV-vermitteltes (p16-positiv) Oropharynxkarzinom AJCC v8
- Pathologisches Stadium II HPV-vermitteltes (p16-positiv) Oropharynxkarzinom AJCC v8
- Stadium IV Nasopharynxkarzinom AJCC v8
- Pathologisches Stadium III HPV-vermitteltes (p16-positiv) Oropharynxkarzinom AJCC v8
- Stadium IVA Nasopharynxkarzinom AJCC v8
- Stadium IVB Nasopharynxkarzinom AJCC v8
- Stadium IVA Hypopharynxkarzinom AJCC v8
- Kehlkopfkrebs im Stadium IVA AJCC v8
- Stadium IVA Oropharynxkarzinom (p16-negativ) AJCC v8
- Stadium IVB Hypopharynxkarzinom AJCC v8
- Kehlkopfkrebs im Stadium IVB AJCC v8
- Stadium IVB Oropharynxkarzinom (p16-negativ) AJCC v8
- Metastasierendes Kopf-Hals-Karzinom
- Karzinom unbekannter Primärform
- Metastasierendes bösartiges Neoplasma im Gebärmutterhals
- Stadium I Hypopharynxkarzinom AJCC v8
- Stadium I Nasopharynxkarzinom AJCC v8
- Stadium II Hypopharynxkarzinom AJCC v8
- Kehlkopfkrebs Stadium II AJCC v8
- Nasopharynxkarzinom Stadium II AJCC v8
- Stadium II Oropharynxkarzinom (p16-negativ) AJCC v8
- Stadium III Nasopharynxkarzinom AJCC v8
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
PRIMARY OBJECTIVES:
I. To determine whether illness perceptions significantly predict adherence to swallowing exercises at 6 months after the end of radiation.
II. To determine whether sickness behaviors (depression, fatigue, pain)'s effect on illness perceptions are mediated by pro-inflammatory cytokines.
III. To determine whether social support moderates the impact of coping on appraisal of coping.
SECONDARY OBJECTIVES:
I. As a secondary aim, to determine the feasibility and utility of cardiac impedance pre-ejection period measurement as a corollary measure for depression and distress.
II. As a secondary aim, to identify potential genetic markers for swallowing dysfunction which has developed by the 6-month follow-up.
OUTLINE:
Participants provide blood samples prior to and at the 6-month visit after receiving radiation therapy. Participants also complete questionnaires either at home, in clinic, or via internet over 30 minutes prior to receiving radiation therapy and within 14 days of blood sample collection.
After completion of study, participants are followed up periodically for up to 2 years.
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Kontakte und Standorte
Studienorte
-
-
Texas
-
Houston, Texas, Vereinigte Staaten, 77030
- Rekrutierung
- M D Anderson Cancer Center
-
Kontakt:
- Eileen H. Shinn
- Telefonnummer: 713-745-0870
-
Hauptermittler:
- Eileen H. Shinn
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Participants with head and neck cancer
Beschreibung
Inclusion Criteria:
- Are dispositioned to receive radiation with curative intent for nasopharyngeal, oropharyngeal, hypopharyngeal, laryngeal, or an unknown primary cancer with cervical metastases
- Are stage II-IVb for non- human papillomavirus (HPV)- related oropharyngeal cancer
- Have HPV- related oropharynx cancer that is T1, have nodal involvement with no distant metastasis or have HPV- related oropharynx cancer that is at least T2 with no distant metastasis
- Are stage II-IVb for laryngeal cancer
- Are stage I-IVb for hypopharyngeal
- Are stage I-IVb for nasopharyngeal cancer
- Have stage I-III unknown primary cancer with cervical
Exclusion Criteria:
- Have other cancer diagnoses, except non-melanoma skin cancer
- Had treatment for previous head and neck cancer or radiation to the head and neck
- Have a history of previous head and neck surgery (excluding biopsy and/or tonsillectomy and/or tracheotomy)
- Have a current oropharyngeal dysphagia unrelated to cancer diagnosis (e.g., dysphagia due to underlying neurogenic disorder)
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: COHORT
- Zeitperspektiven: PROSPECTIVE
Anzahl der Gruppen / Kohorten
Kohorten und Interventionen
Gruppe / KohorteGruppe / Kohorte |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Observational (blood tests, questionnaires)
Participants provide blood samples prior to and at the 6-month visit after receiving radiation therapy. Participants also complete questionnaires either at home, in clinic, or via internet over 30 minutes prior to receiving radiation therapy and within 14 days of blood sample collection. |
Ancillary studies Provide blood samples |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Adherence to swallowing exercises
Zeitfenster: Up to 6 months
|
The primary analytic approach is to use linear mixed models to determine whether illness perceptions significantly predict adherence 6 months. The study will estimate and test the illness perception subscale scores' relationship to adherence using a linear mixed model. In the model, the dependent variable is the patient's self-reported adherence score and independent variables include illness perception, follow-up assessment time point and other covariates such as demographic and medical variables, depression, pain, fatigue, emotional coping, objective coping, appraisal of coping, stress, and lack of social well-being. |
Up to 6 months
|
|
Illness perceptions
Zeitfenster: Up to 6 months
|
The study's statistical tool is mediation analysis: the independent variables are the sickness behaviors (depression, fatigue, pain); the mediators are the cytokine levels, and the outcome variable is illness perception. The study will test the mediator effects based on the product of coefficients method, rather than the classical Baron & Kenny causal steps tests, since the former approach has better statistical power. The study will conduct both single-mediator analysis for each of the mediators, and multiple-mediator analysis with all mediators in the mediating process |
Up to 6 months
|
|
Effect of social support on coping
Zeitfenster: Up to 6 months
|
The moderating effect of social support on coping and appraisal of coping is the statistical equivalent of testing the two-way interaction between these variables and the social support variable. Multivariate linear regression will be used, in which the dependent variable is appraisal of coping at 6 months follow-up, and independent variables include the emotion-focused coping and action-focused sub scales, social support, and their two-way interactions. In the regression, the study will control for baseline variables. In addition, we will also apply the linear mixed model to investigate the moderating effect of these variables longitudinally. The mixed model naturally accounts for the correlation of repeated measures at baseline and 6 months follow-up. |
Up to 6 months
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Mitarbeiter
Mitarbeiter
Ermittler
Ermittler
- Hauptermittler: Eileen H Shinn, M.D. Anderson Cancer Center
Publikationen und hilfreiche Links
Nützliche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Geschätzt)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Stomatognathe Erkrankungen
- Pathologische Prozesse
- Neubildungen nach Standort
- Neubildungen
- Erkrankungen der Atemwege
- Neubildungen nach histologischem Typ
- Kopf-Hals-Neubildungen
- Neubildungen, Drüsen und Epithelien
- Neubildungen der Atemwege
- Neoplastische Prozesse
- Otorhinolaryngologische Erkrankungen
- Rachenneoplasmen
- Otorhinolaryngologische Neubildungen
- Nasopharyngeale Erkrankungen
- Rachenkrankheiten
- Kehlkopferkrankungen
- Neoplasma Metastasierung
- Nasopharyngeale Neoplasmen
- Pathologische Zustände, Anzeichen und Symptome
- Nasopharynxkarzinom
- Karzinom
- Larynxneoplasmen
- Oropharyngeale Neubildungen
- Neubildungen, unbekannte primäre
- Hypopharyngeale Neubildungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- 2016-0597
- 2016-0597 (Andere Kennung: M D Anderson Cancer Center)
- NCI-2018-01260 (Registrierungskennung: CTRP (Clinical Trial Reporting Program))
- R21DE019954 (US NIH Stipendium/Vertrag)
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .